Abstract
To this day, the phase III trial continues to be, as it was more than 60 years ago, the standard for the incorporation of new treatments in oncology. We currently have new tools such as NGS, Liquid Biopsy (LB), Big Data (BD) and Artificial Intelligence (AI) that will allow us to move towards faster and more universal research. This article analyzes the important weaknesses of phase III trials, the importance and current status of targeted therapy, and the contributions to LB decision-making and the knowledge of what happens in real life (RWD) that we facilitates BD and AI. Finally, what could be a clinical trial model that would take advantage of all these tools is proposed.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
